Krensavage Asset Management, LLC Long-Term Concentrated

CIK: 0001609251 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 14, 2024

Total Value ($000): $282 (100.0% shares, 0.0% debt)

Holdings (12)

EXEL EXELIXIS INC 16.2%
Value ($000) $46 Shares 1,899,079 Est. Cost $18.49 Unrealized +17.6%
UTHR UNITED THERAPEUTICS CORP 15.7%
Value ($000) $44 Shares 200,872 Est. Cost $127.97 Unrealized +80.1%
BIIB BIOGEN INC 14.7%
Value ($000) $42 Shares 160,480 Est. Cost $267.94 Unrealized -8.3%
REGN REGENERON PHARMACEUTICALS 14.7%
Value ($000) $42 Shares 47,256 Est. Cost $342.96 Unrealized +138.8%
CAH CARDINAL HEALTH INC 10.1%
Value ($000) $28 Shares 281,476 Est. Cost $56.53 Unrealized +69.3%
— TARO PHARMACEUTICAL INDUS 9.6%
Value ($000) $27 Shares 646,453 Est. Cost $67.97 Unrealized —
ALKS ALKERMES PLC 9.0%
Value ($000) $25 Shares 918,038 Est. Cost $18.83 Unrealized +38.0%
JAZZ JAZZ PHARMACEUTICALS PLC 4.4%
Value ($000) $12 Shares 100,000 Est. Cost $124.79 Unrealized 0.0%
SNY SANOFI-ADR 2.7%
Value ($000) $7 Shares 150,400 Est. Cost $0.05 Unrealized —
ENTA ENANTA PHARMACEUTICALS INC 2.5%
Value ($000) $7 Shares 742,824 Est. Cost $41.72 Unrealized -77.7%
MASI MASIMO CORP 0.3%
Value ($000) $1 Shares 8,000 Est. Cost $93.21 Unrealized 0.0%
— MURAL ONCOLOGY PLC 0.2%
Value ($000) $1 Shares 90,833 Est. Cost $0.01 Unrealized —